醫學系泌尿學科

Medicine and Dentistry

1. Transitional Cell Carcinoma 93%
2. Prostate Cancer 86%
3. Nephroureterectomy 63%
4. Bladder 53%
5. Neoplasm 52%
6. Partial Nephrectomy 47%
7. Laparoscopic Surgery 38%
8. Upper Urinary Tract 34%
9. Kidney Stone 33%
10. Cohort Analysis 33%
11. Transurethral Resection 32%
12. Diseases 32%
13. Scabies 27%
14. Recurrent Disease 27%
15. Biopsy Technique 26%
16. Prostatectomy 26%
17. Clear Cell Renal Cell Carcinoma 26%
18. Cystectomy 25%
19. Prostate Specific Antigen 24%
20. Odds Ratio 24%
21. Androgen Deprivation Therapy 24%
22. Bladder Cancer 23%
23. Hazard Ratio 23%
24. Bleeding 23%
25. Azoospermia 22%
26. Overall Survival 22%
27. Urinary Retention 22%
28. Lithotripsy 21%
29. Urinary System 21%
30. Malignant Neoplasm 21%
31. Prostate Health Index 20%
32. Ureter 20%
33. Tumor 20%
34. Transrectal Ultrasonography 19%
35. Incision 19%
36. Prostate Hypertrophy 18%
37. Thulium 18%
38. Adrenalectomy 18%
39. Retrospective Study 17%
40. Testicular Sperm Extraction 17%
41. Percutaneous Nephrolithotomy 17%
42. Hernioplasty 17%
43. Robot-Assisted Prostatectomy 17%
44. Kidney Function 17%
45. Ligation 16%
46. Sperm Retrieval 16%
47. Adverse Event 16%
48. Body Mass Index 16%
49. Testes 16%
50. Computer Assisted Tomography 16%
51. Nephrectomy 16%
52. Pelvis 15%
53. Magnetic Resonance Imaging 15%
54. Peroperative Complication 15%
55. Bladder Neck Stenosis 15%
56. Spermiogenesis 15%
57. Chemotherapy 15%
58. Disease Free Survival 14%
59. Prostate Biopsy 14%
60. Castration Resistant Prostate Cancer 14%
61. Shock Wave 14%
62. Kidney Tumour 14%
63. Urinary Tract 13%
64. Urinary Tract Infection 13%
65. Non Muscle Invasive Bladder Cancer 13%
66. Infection 13%
67. Bladder Neck 13%
68. Radiation Therapy 12%
69. Multivariate Analysis 12%
70. Morbidity 12%
71. Ureter Stone 11%
72. Adrenal Tumor 11%
73. Comorbidity 11%
74. Urodynamics 11%
75. Elderly Patient 11%
76. Specific Mortality 10%
77. Surgeon 10%
78. PI-RADS 10%
79. Cardiovascular Disease 10%
80. Recurrence Free Survival 10%
81. Clinician 10%
82. Cancer Specific Survival 10%
83. Postoperative Complication 10%
84. Extracorporeal Shock Wave Lithotripsy 10%
85. Urothelial Cancer 10%
86. Matrix Metalloproteinase 10%
87. Postpartum Depression 10%
88. Cyclophosphamide 10%
89. Minimally Invasive Procedure 10%
90. Proportional Hazards Model 10%
91. Hydronephrosis 10%
92. Survival Rate 9%
93. Inguinal Hernia 9%
94. Hormone Therapy 9%
95. Prospective Study 9%
96. Messenger RNA 9%
97. Treatment Outcome 9%
98. Diabetes Mellitus 9%
99. Pheochromocytoma 9%
100. Aluminum 9%

Keyphrases

1. Taiwan 100%
2. Prostate Cancer 83%
3. National Cohort Study 55%
4. Upper Tract Urothelial Carcinoma 52%
5. 95% Confidence Interval 44%
6. Taipei 42%
7. Androgen Deprivation Therapy 38%
8. Risk Factors 33%
9. Nephroureterectomy 33%
10. Tumor 32%
11. Prostate 30%
12. Transurethral Resection of Prostate 28%
13. Laparoscopic Nephrectomy 27%
14. Population-based Study 24%
15. Taiwanese 24%
16. Operative Time 24%
17. Single-center Experience 24%
18. Transitional Cell Carcinoma 23%
19. Bladder Cancer 23%
20. Urothelial Carcinoma 22%
21. Benign Prostatic Hyperplasia 22%
22. Prostate Cancer Patients 22%
23. Non-muscle Invasive Bladder Cancer (NMIBC) 21%
24. Kidney 21%
25. Sperm Retrieval 21%
26. Urinary Retention 21%
27. Scabies 20%
28. Ureter 19%
29. Hazard Ratio 19%
30. Patients with Prostate Cancer 19%
31. Non-obstructive Azoospermia 19%
32. Oncological Outcomes 18%
33. Radical Prostatectomy 18%
34. Bladder Cuff Excision 18%
35. Neuroendocrine Prostate Cancer 18%
36. Prostate Cancer Cells 18%
37. Thulium Laser 17%
38. Monoamine Oxidase A (MAO-A) 17%
39. High Risk 16%
40. Spermatogenesis 15%
41. Disease-free Survival 15%
42. Castration-resistant Prostate Cancer 15%
43. Arsenic 15%
44. Cancer-specific Survival 15%
45. Radical Cystectomy 15%
46. Cardiac Magnetic Resonance Imaging (cMRI) 15%
47. Aggressive Prostate Cancer 15%
48. Azoospermic Men 15%
49. Porcine Model 15%
50. Stone-free Rate 15%
51. Microdissection Testicular Sperm Extraction (micro-TESE) 15%
52. Laparoscopic Surgery 14%
53. Overall Survival 14%
54. Complication Rate 14%
55. Newly Diagnosed 14%
56. Renal Cell Carcinoma 13%
57. Percutaneous Nephrolithotomy 13%
58. Pharmacokinetics 13%
59. Body Mass Index 13%
60. Postoperative Outcomes 13%
61. Varicocele 13%
62. Predictive Factors 12%
63. Comorbidity 12%
64. Odds Ratio 12%
65. Hand-assisted Retroperitoneoscopic Donor Nephrectomy 12%
66. Bladder Neck Contracture 12%
67. Adjusted Hazard Ratio 12%
68. Urolithiasis 12%
69. Laparoscopy 12%
70. Multivariate Analysis 11%
71. Laparoscopic Partial Nephrectomy 11%
72. Azoospermia 11%
73. Overexpression 11%
74. Laparoscopic Radical Prostatectomy 11%
75. Laparoscopic Adrenalectomy 11%
76. Acute Urinary Retention 11%
77. Multicenter Cohort Study 11%
78. No Significant Difference 11%
79. Perioperative Complications 11%
80. Urothelial Cancer 11%
81. Erectile Dysfunction 10%
82. Blood Loss 10%
83. Clinical Outcomes 10%
84. Younger Schoolchildren 10%
85. Traditional Chinese Medicine 10%
86. After Surgery 10%
87. Renal Tissue 10%
88. Meta-analysis 10%
89. Robotic Partial Nephrectomy 10%
90. Radiotherapy 10%
91. Dysregulated Proteins 10%
92. Surgical Outcomes 10%
93. Adjusted Odds Ratio 10%
94. Recurrence-free Survival 10%
95. Arsenic Exposure 10%
96. Prostate Cancer Screening 10%
97. Clinical Experience 10%
98. Latanoprost 10%
99. Matrix metalloproteinase-2 (MMP-2) 10%
100. Medical Utilization 10%